IMpower150 Trial Delays Progression in Advanced NSCLC With Atezolizumab/Bevacizumab Combo

Excerpt:

“In topline results announced from the phase III IMpower150 trial, atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) and chemotherapy delayed progression or death when compared with bevacizumab and chemotherapy alone for patients with advanced nonsquamous non–small cell lung cancer (NSCLC).

“The co-primary endpoints for the IMpower150 study were progression-free survival (PFS) and overall survival (OS). Although exact numbers have not yet been released, Roche, the manufacturer of the anti–PD-L1 and anti–VEGF agents, called the reduction in progression or death with the addition of atezolizumab a ‘clinically meaningful reduction’ in a press release. At the interim analysis, data for OS were not yet mature, with the company labeling the findings as ‘encouraging.’ ”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.